Literature DB >> 24120966

Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats.

D Leonardi1, M E Bombardiere, C J Salomon.   

Abstract

Benznidazole (BZL) is the drug of choice for the treatment of Chagas' disease, a neglected parasitic infection. It is poorly soluble in water, which may have a direct impact into its bioavailability. Thus, the aim of this study was to evaluate the impact of stoichiometric and non-stoichiometric BZL-cyclodextrins (CDs) complexes on the bioavailability of BZL. The interaction of BZL with the CDs was investigated using differential scanning calorimetry (DSC), scanning electron microscopy (SEM), X-ray diffractometry (XRD), phase solubility and dissolution studies. The oral bioavailability of BZL from these complexes was examined in rats. Both BZL solubility and dissolution increased by CD complexation. The inclusion complexes were found to improve the dissolution rate of BZL by 4.3-fold in comparison with BZL alone. Complexation of BZL with CDs derivatives increased its plasma concentrations when fed to rats, with AUC0-5 values increasing up to 3.7-fold and Cmax increasing 2.5-fold in comparison with BZL alone. It should be note that a remarkable increase in these parameters was observed in the case of the non-stoichiometric complexes. Thus, these CDs complexes could be used to efficiently deliver BZL in patients suffering from Chagas' disease.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benznidazole; Bioavailability; Chagas’ disease; Complexation; Cyclodextrins; Dissolution rate

Mesh:

Substances:

Year:  2013        PMID: 24120966     DOI: 10.1016/j.ijbiomac.2013.10.007

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

1.  Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.

Authors:  María L Scalise; Eva C Arrúa; Marcela S Rial; Mónica I Esteva; Claudio J Salomon; Laura E Fichera
Journal:  Am J Trop Med Hyg       Date:  2016-05-31       Impact factor: 2.345

2.  Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.

Authors:  Luísa Perin; Rodrigo Moreira da Silva; Kátia da Silva Fonseca; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease.

Authors:  Teresa Vinuesa; Rocio Herráez; Laura Oliver; Elisa Elizondo; Argia Acarregui; Amaia Esquisabel; Jose Luis Pedraz; Nora Ventosa; Jaume Veciana; Miguel Viñas
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

4.  Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.

Authors:  Xiaomo Li; Sijia Yi; Débora B Scariot; Santiago J Martinez; Ben A Falk; Cheryl L Olson; Patricia S Romano; Evan A Scott; David M Engman
Journal:  JCI Insight       Date:  2021-05-10

Review 5.  Cyclodextrin⁻Drug Inclusion Complexes: In Vivo and In Vitro Approaches.

Authors:  Simone Braga Carneiro; Fernanda Ílary Costa Duarte; Luana Heimfarth; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior; Valdir Florêncio da Veiga Júnior; Ádley Antonini Neves de Lima
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

6.  Characterization and trypanocidal activity of a β-lapachone-containing drug carrier.

Authors:  Juliana M C Barbosa; Caroline D Nicoletti; Patrícia B da Silva; Tatiana G Melo; Débora O Futuro; Vitor F Ferreira; Kelly Salomão
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.752

7.  Photostability and antioxidant activity studies on the inclusion complexes of trans-polydatin with β-cyclodextrin and derivatives.

Authors:  Shujing Li; Li Yuan; Bing Zhang; Wei Zhou; Xinrui Wang; Dongsheng Bai
Journal:  RSC Adv       Date:  2018-07-19       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.